Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
Biotherapeutic Department of Chinese PLA General Hospital, Beijing, Beijing, China
UCSF Medical Center, San Francisco, California, United States
Yale School of Medicine, New Haven, Connecticut, United States
Georgetown University Hospital, Washington, District of Columbia, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Local Institution - 008, Baltimore, Maryland, United States
Local Institution - 009, Duarte, California, United States
Local Institution - 011, New York, New York, United States
University of Alabama, Birmingham, Alabama, United States
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
UF Health Shands Cancer Hospital, Gainesville, Florida, United States
Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Gene therapy research center, Shariati hospital, Tehran university of medical sciences, Iran, Tehran, Iran, Islamic Republic of
Research Institute for Oncology- Hematology and Cell Therapy (RIOHCT), Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
Memorial Sloan Kettering Cancer Center, New York, New York, United States
centre hospitalier universitaire vaudois (CHUV), Lausanne, Vaud, Switzerland
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
University of Alabama at Birmingham, Birmingham, Alabama, United States
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.